Plain-English translation of NCT06989437 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new medication designed to help people with advanced pancreatic cancer that has spread to other parts of the body. Many patients with this cancer experience severe weight loss and weakness (called cachexia), which can make it harder to tolerate chemotherapy and stay strong. The medication is given as an injection every 4 weeks, alongside the standard chemotherapy drugs you would already be receiving.
Pancreatic cancer patients often lose significant weight and muscle mass, which weakens their body and can limit their treatment options. This medication aims to reverse that weight loss and help patients feel stronger and more able to fight their cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the study medication as a subcutaneous (under-the-skin) injection every 4 weeks, starting on the same day you begin your next cycle of chemotherapy. Some participants will receive the new medication at one dose, others at a different dose, and some will receive a placebo (inactive injection) — you won't know which group you're in. The trial includes both a 'blinded' phase (where neither you nor your doctor knows which treatment you're getting) and an optional extension phase where the medication is open-label (everyone knows they're receiving it).
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States